Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
sentiment_stocks,
I agree. Linda has many connections to financing, research groups and much more. She always has more options than most bulletin board commenters are aware of. Best wishes.
beartrap12,
I don’t have the original building plan in front of me but the final buildout was expected to have 24/7 manufacturing with over 230 employees as I recall. That number may be in the 300s.
Right now Sawston has two B grade suites (suites being multiple clean rooms within) and 2 C grade suites of clean rooms either done or in the works with plenty of room for expansion. Once production of the GMP manufacturing units are on an assembly line the ramp up should not take too long. I would assume they are at least close to this position now.
Future clean room suites will likely be C grade with the existing B grade rooms used for both artisan and Flaskworks for comparability and backup. I defer to others who might have more experience with specific manufacturing development processes to point to a closer expected time frame for completion and validation based on the info we have in hand. Best wishes.
georgebailey,
Thanks, just saw this and your response of 50+50 monthly (1A and 1B) is the one basically mentioned by NWBO based on artisan methodology. Digitization and reduced footprint on space by Flaskworks vs artisan makes this much larger number possible not only due to space requirements but also reduced need for qualified personnel which has been a long time limiting factor and one that I have mentioned for quite some time now with regard to product release which NWBO themselves told us. Best wishes.
exwannabe,
😊. I think Advent is about ready to be able to treat 12,000 patients per year rather than nearly 4 year survivors… although treatment of lower grade gliomas and GBM/rGBM might lead to 12,000 patients per year as the new survival numbers get stretched out. At that point a push for a cure and not chronic treatment would be pressed for hard. Anyone working on that?; ). Best wishes.
iclight,
Devices are low bar and many wanted any tool available for GBM that might work or help something else work in at least some case situations. Some folks in favor of approving Optune talked about 5 year survivors being seen which of course is rare and that seemed to be enough for their support. DCVax-L has many more long term survivors and cleared a much higher bar with actual 5 year+ data. Nuff said. Best wishes.
flipper44,
NWBO and Dr. Linda Liau started with first do no harm and safety first then build from there. FDA is now looking more and more like a rubber stamp for big pharma and slow as molasses to approve safe treatments from small companies and just as slow to discontinue conditional approvals and dangerous treatments that they already have approved from big companies. Not a good look especially when obvious issues arose years ago, some of which should have been anticipated, and were not dealt with promptly. DCVax-L trials have been going on so long no one should have any doubt as to safety and improving efficacy being seen with tweaks and combos. Best wishes.
dennisdave,
I guess you missed the part about Walgreens preparing for DCVax-L distribution and point of sale instructions. I am pretty sure a franchise model based on Advent and perhaps CRL being training centers as well as manufacturing partners might be more than adequate to train big pharma franchisees. Linda also has other connections to get the help needed from and every trial site is trained in the basics of artisan administration and followup. A little training on how digitization works and good to go because these centers will be serving as the sales team as initial points of contact while eventual SOC designation will take care of much of the rest. By the way, this new language is in the risk section because of the likelihood of approval in the first place. Wrap your head around that; ). Best wishes.
RobotDroid,
The chart Sojourner55 showed originally of the current trend pointed to a continuation downward to about $.40 maybe even $.385 which is right around where May 10th 2022 took it to. When other comparative looks indicated that a breakout might occur this FUD not change the original chart. Everything depends on news and cycles within trends are happening too. Watch and learn. Best wishes.
exwannabe,
Come on exwannabe, own your “guess” and while you are at it your purpose for being here all these years. Inquirig minds want to know; ). Best wishes.
georgebailey,
There will be lots of talent looking to join the ground floor of the future in cancer treatment and well beyond. How long before Dr. Linda Liau and Dr. Bosch get their dues for what they have done with L and Direct. Best wishes.
Inquirig,
My grandkids sure think so!; ). Best wishes.
Inquirig,
You are having an extremely difficult time ignoring me like you said you would; ). Those who are the “smartest investors” know when to switch allegiances to maximize profits while minimizing risk. They aren’t ready yet and myself and others have been willing to take on the risk that they have not. My investment has been up and down in support of this company while theirs has mainly been up in support of making money all along the way. As maverick_1 is fond of saying, “different strokes for different folks”. Best wishes.
Inquirig,
My premise is that DCVax-L and Direct are already working well for some, will be validated as hugely commercially successful and that with that success your moniker will fade into oblivion. Time will certainly tell whether or not your contradictive viewpoint and premises will be sustained or not. I predict that your opinions, like dust, will be swept away with the winds of change created by approvals of DCVax-L then later Direct. Let time and truth be the judge and may memories not fade but rather be fully restored at the proper time for judgment. Best wishes.
learningcurve2020,
Why? Don’t you like my nice bright tie dye colors I painted the cabal tribe with?; ).
Inquirig,
Still having trouble ignoring me I see; ). How much less dilution would there have been over the last 9 years if a true white knight who understood the need for developing manufacturing breakthroughs and the time to develop that had stayed with NWBO to get past the big pharma and hedge fund cronies blockade?
For Mr. Neil Woodford this “bump in the road” was too much and his idea to move NWBO in a different direction was met with Linda putting him and his funds in time out. She knew what she was doing and kept full value of this platform in retail shareholder hands much to the chagrin of others who thought that their dirty tricks and lawbreaking actions would be enough to derail this plan and this company. Well Mr. Neil Woodford didn’t do very well compared to Linda which is proven out by the fact that he is no longer fiduciary of his former funds which collapsed while Linda has taken L to the approval stage with a worldwide “franchise” manufacturing model. That model can be implemented nearly simultaneously with approval since Edens certification has nearly caught up to the approval process. I would say that is pretty good preparation and logically sound when facing forces that would like to control the sea change coming but are now forced to compete against each other. These and other forces thinking to benefit from stock manipulation, perhaps designed to help those with the plan to control this change, are about to find out that pleasure for a season can end very abruptly and to greater detriment than the gain achieved.
I believe that longs believe Laura Posner and Cohen will eventually expose much of the plan to subordinate the plans of NWBO in the court of law and the court of public opinion for what it is, a massive illegal attempt to hold back a promising new treatment approach that harnesses the immune system of each patient treated instead of killing it off with poisons.
The above, in a big nutshell, is the cause of all this dilution that you constantly rant about being Linda’s fault. You like to blame Linda instead of give credit for this to those who worked hard to strip away institutional opportunity to support NWBO because of share price. Instead you give credit to these same who besmirch the names of those working so hard to bring a safe and efficacious treatment to patients who deserve better than the painful and debilitating treatments they receive now. You also enjoy emphasizing the obvious limitations that a small company has with such big ambitions. This is what you and the cabal do and you have made that your job here.
In spite of all your attempts, longs will continue to support NWBO because of the science that wins out in the end because there is a management team that can persevere. Linda has proven herself fully capable of this and will outlive your moniker on this board. That is a given that you and all those with you will soon find out.
Every long still accumulating at these prices and holding a few years will very likely be dancing in the streets, starting later this year in my opinion, and the party will last long after your moniker and many others with you have all disappeared.
Approval of vaccine MAA applications come in at nearly a 100% rate which you all know. Chew on that for a bit before your next post that deliberately fails to mention this while you complain about all the dilution that you and the gang want NWBO to take credit for instead of all the real perps; ). Best wishes
Inquirig,
Yes the stock is tanking as expected because of the forces at work which you represent and because current longs are pretty much saturated sponges just waiting for “the market” to become aware of what great due diligence on this board has revealed. This includes commercial scale manufacturing readiness on a global scale with franchising of the Advent model and big improvements in outcomes expected. This will come from what NWBO has learned in the interim, post Phase 3, about use of Poly ICLC and checkpoint combos along with CSF-R1 and proper T-cell activation/maturation with RevImmune’s IL-7 product.
By the way, “the market” represents followers in this case because retail has taken the lead, no big pharma can afford to pay the price this platform is worth and institutions are mostly being kept out of the picture for now because of the price which thanks to you and others is giving multiple generations in my family and others the opportunity to become financially secure and a blessing to many others besides when the expected news finally arrives and your moniker disappears; ). Best wishes.
Inquirig,
You are having quite a bit of trouble keeping me on ignore it seems; ). The PIP trial(s) don’t always have to start before approval but they must be prepared for. Try again. Best wishes.
sharpie510,
“Starting in 2025…”, cryo storage prominent at the end of the presentation. Not sure the cryo storage is needed for the other prospects listed in the 2023 piece. Definitely needed for DCVax-L and they have plenty of it; ). Seems like 2025 and the word “cure(s)” are cornerstones for this new division. Best wishes.
learningcurve2020,
Don’t worry about NWBO as they have had extensive talks with MHRA over the years and formally announced acceptance of the SAP which in those talks also would have included the rational for changes in primary objectives/endpoints which is why the PIP was accepted. Try another more believable distraction next time ; ). Best wishes.
georgebailey,
Right now DCs are being activated and matured optimally by NWBO and T-cells are being improved by RevImmune. By combining the two the immune response can be better activated to provide more complete responses to immunotherapy. The idea for now is about combining DCVax-L with activated and amplified T-cell populations that are supercharged then educated by DCs. Sounds good to me; ). Best wishes.
StonkMaster,
Yes, I noticed the bears were quiet before when GermanCol announced his move and both bears and some longs seem to be very quiet today after this move was justified by FDA approval and price action in this ticker. Best wishes.
manibiotech,
For me that is almost entirely true because of my long term plans to accumulate before approvals and then at certain points after the initial rise to discounted net present value. You seem to forget that there were several times above and below $2 where there were many who sold. Matter of fact, May 10th 2022 was a big manipulated sell day.
I personally plan for much of the future value of our holdings to go to charitable causes and some to the kids and grandkids so I have no plans to sell anytime soon unless something triggers a big squeeze to well above net present value estimations. Anyway, plenty of opportunities to sell in the not too distant future. In the mean time, anything below $.62 is a screaming buy in my opinion because of the long term trend started in April/May of 2020 but of course that does not stop the March to $.40 we appear to be on now until actual MHRA news. Longer term we know that any approvals will bring in substantial interest and the price will respond accordingly. You will likely have a very comfortable time to sell after that if you so choose. Understand that this is not investment advice but rather only personal opinion and shared plans with regard to our investment. Best wishes.
HappyLibrarian,
Something like “buy when everyone else is selling and sell when everyone else is buying”!; ). The manipulators would have us always believe in the intelligent market but that is just a pat on the back for those who don’t do the above so that they feel can good about being part of the manipulation in between highs and lows. Best wishes.
exwannabe,
Just admit that what was mentioned publicly about “lawful operating status” is just a formality that helps in transition to a merger, buyout or other like franchising so that those involved have validated approval of operations by the authorities. No change necessary, just certification. Best wishes.
dstock07734,
Not forgetting any of that. Just too big of a picture for many to imagine but that is exactly why I said that 3 years from first approval would see such a huge difference in price. The market will really understand better what they are looking at by then even if current longs don’t all hold out for that much bigger valuation that is coming in my opinion. Best wishes.
georgebailey,
The common word of the day between NWBO and BMS… “franchise”. Seems clear enough language to me and addresses the economic balance of power concerns that big pharma has been facing; ). They stay alive as long as they keep pace with NWBO’s market development expansion model with favorably split revenue and entry fees to get to the table. Best wishes.
georgebailey,
…and Edens works with both DCs and T-cells. Talk about being prepared with advanced commercialization of improved product line; ). Best wishes.
dstock07734,
“…discovering IL-7 as the master regulator of T-cell homeostasis”. Now why would the master regulator of T-cell homeostasis have anything to do with the master immune cells of governed immune response (DCs). RevImmune with NWBO using Edens anyone?; ). Best wishes.
renaissance1,
Just waiting on the MHRA decision to be formalized so the unaware and unbelievers can finally become a “woke market” and the paid protagonists are no longer useful. Then big pharma finally has to publicly admit their need of NWBO by making legit offers because of their products being reduced to secondary positions or even unneeded by the DCVax platform with respect to cancer treatment. Best wishes.
dstock07734,
Anyone who underestimates Linda Powers’ ability to use leverage does so at to their own loss or detriment. Your example is just one of many. MHRA vs FDA and PEI being the really big one; ). Best wishes.
tryn2,
Just an old fiduciary duty claim against NWBO that was settled for $152,000 without NWBO admitting to legally needing to make changes. Getting all the old litigation cleaned up for the new deals being planned probably. Best wishes.
Inquirig,
So many better ways for wealthy folks from this management team to have built more wealth than what Linda, Les and others did to protect this tech and get it to approval stage. Did Les, Alton Boynton, Dr Bosch and all the directors get rich by Cognate being sold?; ). So why didn’t they ditch from being upset about the sale? Why did Shashi Murthy take shares and cash instead of all cash for Flaskworks? The quite obvious answer is that he and the others saw and still see value in the shares but like many investors wanted to take some cash for time and finances invested up to that point of development so he could be working with “house money” so to speak.
You and your “friends” are sounding more and more desperate to make the current silence seem bad when in fact the silence is just creating a golden opportunity for some with your help. Best wishes.
GermanCol,
I appreciate the honesty in this post and all the years of your shared great due diligence. Every investor faces different circumstances and you have obviously thought out your move out carefully based on your circumstances. Wishing you all the best and hope you will continue posting when you feel moved to do so. Best wishes.
learningcurve2020,
Linda extending an olive branch to AF would be a fool’s errand and I believe you know that; ). If the public rebuff and reproof by the head of NWBO’s DMC was not enough to change his attitude then giving him more credit for doing harm by acknowledging him with an olive branch would only give him more ammo to attack the company with and make the CEO look weak.
Bob Dylan said it well “You’ve got to serve somebody. Now you can serve the devil or you can serve the Lord but you’ve got to serve somebody”. You shall know them by their fruits…in this case, a certain claim regarding grapefruit among others😊. Best wishes.
beartrap12,
The only example that I remember was one in which some additional factors were involved and I believe it was exwannabe that pointed out that shares were being traded right before the halt in trading when those shares were known to be at risk but the time frame was not well known. As I recall, the issue was that there were more shares sold short in that ticker than total shares issued by the company which started all the problems when ownership resolution needed to occur. I don’t remember the ticker off hand but it was discussed here often over the years in the context of naked shorting. Best wishes.
beartrap12,
Good to read this and as much as I admire Larry Smith I would sure like to hear or read what Wes Christian or Cohen has to say about this too. Linda has stated that the shorting of shares held in IRAs and margin accounts may be temporary but were being used or potentially used to drive share price down to hurt the company while also making money doing so by simply replacing shares after taking them out of margin or less active accounts at least for a while. The idea of having huge inventories of shares sold but not repurchased that may have been held for a long period of time is still something to be looked into I would think especially if liabilities grow exponentially like they did with AMC and others where the free market was interfered with to allow settlement to prevent bigger losses for those holding large losing positions. Best wishes.
manibiotech,
Cycles within trends happen. Sojourner55’s chart from when he checked back in clearly showed a trend that could move back to around $.40 before a full breakout. The breakout looked to be coming sooner based on a chart comparison to an earlier time. The breakout did not fully occur and the return to longer trend is back in play. Anything below $.62 is below the long term uptrend from March/April of 2020 which means that NWBO is trading at a huge discount to just the longer term trend let alone true intrinsic value. Yes we know dilution is happening but this discount goes way beyond the rate of dilution considering that an MAA decision is expected in the second to third quarter of this year. Longs have simply reached a saturation point while we wait and the bears are taking advantage. Best wishes.
hankmanhub,
Believe it or not, the common understanding about all of this is as exwannabe has explained at times BUT.. there are some intricacies in governance around this issue that apparently leave some doors open. That is where the trouble is and I am not an expert to try and explain this in legal terms let enough bring it down to simpler terms more easily understood. I have not seen exwannabe delving more deeply into those details either as far as I have seen.
I believe Cohen, Wes Christian, Les Goldman and Linda Powers have studied all of this to different degrees. There are very few expert specialists in this whole area of stock manipulation and this may be one reason why DOJ has been so tardy to the party. The video shared recently showing folks hitting the f3 key to find more shares that were actually ghost shares when located shares went to zero is just one example confessed to by a corporate trader. How much more is there to fess up to?: (. Best wishes.
antihama,
This is only my opinion based on all that I have read and should not be taken as absolute fact as there are many factors to consider. What is described in that post works in favor of naked shorts in my opinion IF a “Friendly” buys the company ie a big pharma willing to make good at a cheap price so that all shares that otherwise would be unaccounted for are actually paid for as the books get straightened out. If a non friendly transaction occurs then those unaccounted for shares don’t get covered but rather get “discovered” as not existing leaving investors with a potentially very big loss. The truth comes out if and when those shares don’t get located and covered fast enough from those trying to cover their tracks by buying as the price is rising. The backup plan for them is probably found in the liability agreements and bankruptcy laws. One thing I believe is certain is that those who have their shares lent out and are trying to get them back will not be covered at all in this circumstance. Best wishes.
tryn2,
As explained about naked short position being smoked out, that is only one reason for this potentially expected merger. The other and more important reason is that RevImmune focuses on improved T-cell activation and expansion while NWBO has been focused on DC activation and maturation. Edens works for both DCs and T-cells so the synergy regarding improved combined outcomes is expected to expand access to treatment to many who were not originally allowed into the Phase 3 trial as now many more low absolute lymphocyte count patients will be able to benefit from treatment and all will benefit from improved T-cell activation with proper IL-7 usage which is what RevImmune specializes in. Best wishes.